clioquinol + flumethasone pivalate

Locacorten Vioform is a well-established fixed-dose combination therapy containing flumethasone pivalate (0.02%) and clioquinol (1% or 3%). Flumethasone pivalate is a moderately potent, difluorinated corticosteroid that acts as a glucocorticoid receptor agonist, providing localized anti-inflammatory, antipruritic, and vasoconstrictive effects. Clioquinol (iodochlorhydroxyquin) is a halogenated hydroxyquinoline with broad-spectrum antibacterial and antifungal properties, acting primarily as a metal chelator and DNA intercalator to disrupt microbial replication and cell wall integrity. Originally developed by Ciba-Geigy (now Novartis), the combination is approved for treating external ear infections (otitis externa), fungal ear infections (otomycosis), and various corticosteroid-responsive inflammatory dermatoses complicated by secondary bacterial or fungal infections. It is currently marketed and distributed globally by several specialty pharmaceutical companies, including Daleco Pharma in the Netherlands.

Brand names

Locacorten VioformLocacorten-VioformLocacortene VioformeLocorten VioformLocorten VioformioLocorten VioformoLocortene VioformoViotic

Other names

clioquinol + flumetasoneclioquinol + flumetasone pivalateclioquinol + flumethasoneclioquinol + flumethasone pivalateclioquinol and flumethasone pivalateflumetasone pivalate + clioquinolflumethasone pivalate + clioquinolflumethasone pivalate and clioquinoliodochlorhydroxyquin + flumethasone pivalate